Inozyme PharmaÂ Inc (INZY) Peer Comparison

$4.00

$0.00 (0.00%)

As on 02-Jul-2025 09:30EDT

Market cap

$258 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

8.1

Div. Yield

0 %

Edit

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Market cap ($ Mln)	258	3,541
Revenue ($ Mln)	--	220
Net Profit ($ Mln)	-106.72	-253.93
Net Margin (%)	--	-115.60
RoE (%)	-186.26	-53.46
Price to Earnings	--	--
Price-To-Book	8.12	8.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Operating Revenue	0.00	219.67
Cost of Revenue	0.67	14.88
Gross Profit	--	179.04
Operating Expenses	107.38	469.53
Operating Profit (EBIT)	-107.38	-264.74
Other Income	0.00	0.00
Profit before Tax	-106.72	-253.93
Provision for Tax	-0.01	0.00
Profit after Tax (Net Income)	-106.72	-253.93
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Shareholder's Funds	31.80	417.40
Minority Interest	0.00	0.00
Non-Current Liabilities	20.59	5.69
Current Liabilities	42.78	82.27
Total Liabilities	123.18	587.28

Assets ($ Mln)

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Non-Current Assets	1.53	149.04
Current Assets	93.64	356.32
Total Assets	123.18	587.28
Total Debt*	46.95	7.39
Net Current Assets	50.86	274.05

Cashflow ($ Mln)

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Cash From Operating Activities	-91.91	-175.60
Cash Flow from Investing Activities	67.00	64.55
Cash from Financing Activities	11.40	4.76
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
ROCE (%)	-69.93	-46.00
ROE (%)	-186.26	-53.46
ROA (%)	-65.21	-38.67
EBIT Margin (%)	--	-120.52
Net Margin (%)	--	-115.60
Cash Profit Margin (%)	--	0.00

Growth Ratios

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Revenue Growth (%)	--	480.11
EBIT Growth (%)	-39.51	26.49
Net Profit Growth (%)	-38.39	25.11
EPS Growth (%)	-23.75	31.55
Book Value Growth (%)	-74.29	-27.54

Valuation Ratios

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Price / Earnings	-1.71	-10.38
Price / Book Value	3.01	5.57
Dividend Yield (%)	--	--
EV/EBITDA	-1.04	-8.55
Market Cap ($ Cr)	--	--

Solvency Ratios

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Debt to Equity	0.65	0.00
Short term debt to equity ratio	0.83	0.00
Current Ratio	2.19	4.33
Quick Ratio	2.19	4.18
Interest Coverage	-17.92	-253.44

Operating Efficiency Ratios

	Inozyme PharmaÂ Inc (INZY)	SpringWorks Therapeutics (SWTX)
Debtors to sales (%)	--	18.37
Asset Turnover	0.00	0.33
Receivable days	--	49.73
Inventory Days	--	193.76
Payable days	--	285.86
Cash Conversion Cycle	--	-42.37

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly